Metabolon Appoints Rangaprasad Sarangarajan to Chief Scientific Officer
Metabolomics and precision medicine company Metabolon has appointed Rangaprasad (Ranga) Sarangarajan as its chief scientific officer (CSO).
Sarangarajan previously served as CSO and senior vice president of clinical and translational sciences at BERG, where he led the development of a multi-omic, biology-based platform for identifying disease-specific targets and novel therapeutics, and developing diagnostics. He also helped establish that company's pipeline of assets in various diseases and indications, and led several programs through early IND, including enabling a first-in-human Phase I and proof-concept Phase II clinical program.
Sarangarajan obtained a PhD in pharmaceutical sciences from the University of Cincinnati and is part of over 40 pending or approved patents.